Q-omics provides the consensus-scored ZNF470 profile across patient tissues and cancer cell-line models. ZNF470 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF470 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, ZNF470 RNA expression shows 20,736 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where ZNF470 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF470 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF470 survival associations across molecular data types. ZNF470 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF470 RNA expression–survival associations across cancer types. High ZNF470 expression shows unfavorable associations in LGG, LUSC, STAD and UVM, but favorable associations in KIRC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF470 RNA expression.
This table summarizes ZNF470 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF470. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF470 shows lower tumor expression in KICH, KIRP, HNSC, BRCA and BLCA and higher tumor expression in CHOL. The KICH box plot shows higher ZNF470 RNA expression in normal versus tumor tissue (log2 FC = −0.956, t-test p < 0.001).
This table shows molecular features associated with ZNF470 in patient tissues and cancer cell lines. In patient samples, ZNF470 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF470 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
